New cell therapy shows promise for tough blood cancers
Disease control
Ongoing
This early-phase study tests a new treatment called FT819 for people with certain blood cancers (B-cell lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia) that have not responded to standard therapies. The treatment uses specially engineered immune cells to…
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC